NOV Inc.

NOV

$21.49

-1.01%

N/A-$0.22

Energy

Oil & Gas Equipment & Services

NYSE

Negociación activa

NOV Inc. is a global leader in designing, manufacturing, and marketing essential systems, components, and products for the oil and gas drilling ...

Noticias recientes de NOV

Zacks Investment Research24/7/2026Neutral

NOV to Report Q2 Earnings: What's in Store for the Stock?

NOV faces a key Q2 test as delayed shipments, strong order trends and cost cuts collide with ongoing logistics and drilling headwinds.

Zacks Investment Research21/7/2026Neutral

Nov Inc. (NOV) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Nov Inc. (NOV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research14/7/2026Neutral

NOV Stock Rallies 49% in a Year: Time to Buy or Move On?

NOV's technology gains, rising earnings estimates, strong backlog and shareholder returns strengthen its long-term outlook despite trailing some peers.

The Motley Fool27/6/2026Neutral

NOV vs. SLB N.V.: Which Energy Stock Is a Better Buy in 2026?

NOV provides a conservative balance sheet with a current ratio of roughly 2.4x and low debt levels. SLB N.V. leverages a massive global footprint to generate substantial free cash flow nearing $4.8 billion.

GlobeNewsWire23/6/2026Neutral

Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease

-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation on track, with first participants expected to be dosed in the second half of 2026 -- Antwerp, Belgium, June 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn's Disease (FSCD). Approximately 46% of Crohn's disease patients have FSCD, or fibrotic strictures in the intestinal tract, which can cause obstructive symptoms leading to dietary change, malnutrition and surgery.

Zacks Investment Research•7/24/2026

NOV to Report Q2 Earnings: What's in Store for the Stock?

NOV faces a key Q2 test as delayed shipments, strong order trends and cost cuts collide with ongoing logistics and drilling headwinds.

NOV Inc.

Noticias recientes de NOV

NOV to Report Q2 Earnings: What's in Store for the Stock?

Nov Inc. (NOV) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

NOV Stock Rallies 49% in a Year: Time to Buy or Move On?

NOV vs. SLB N.V.: Which Energy Stock Is a Better Buy in 2026?

Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease

NOV to Report Q2 Earnings: What's in Store for the Stock?

Nov Inc. (NOV) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

NOV Stock Rallies 49% in a Year: Time to Buy or Move On?

NOV vs. SLB N.V.: Which Energy Stock Is a Better Buy in 2026?

Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease

NOV Announces Second Quarter 2026 Earnings Conference Call

NOV Stock Gains 32% in Six Months: Should Investors Hold or Move On?

Why Is Nov Inc. (NOV) Up 4.1% Since Last Earnings Report?

NOV Declares Regular Quarterly Dividend and Supplemental Dividend

Solaris Energy Q1 Earnings Crush Estimates on Power Growth

NOV Q1 Earnings Miss Estimates, Revenues Beat, Decrease Y/Y

While Asia and Europe scramble for natural gas, the US glut has nowhere to go

NOV Inc. (NOV) Q1 2026 Earnings Call Transcript

Compared to Estimates, Nov Inc. (NOV) Q1 Earnings: A Look at Key Metrics

Nov Inc. (NOV) Lags Q1 Earnings Estimates

NOV Reports First Quarter 2026 Earnings

NOV Reports First Quarter 2026 Earnings

Supply Chain de NOV

Upstream

Downstream

Proxies

Noticias recientes de NOV

NOV to Report Q2 Earnings: What's in Store for the Stock?

Nov Inc. (NOV) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

NOV Stock Rallies 49% in a Year: Time to Buy or Move On?

NOV vs. SLB N.V.: Which Energy Stock Is a Better Buy in 2026?

Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease

NOV to Report Q2 Earnings: What's in Store for the Stock?

Nov Inc. (NOV) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

NOV Stock Rallies 49% in a Year: Time to Buy or Move On?

NOV vs. SLB N.V.: Which Energy Stock Is a Better Buy in 2026?

Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease

NOV Announces Second Quarter 2026 Earnings Conference Call

NOV Stock Gains 32% in Six Months: Should Investors Hold or Move On?

Why Is Nov Inc. (NOV) Up 4.1% Since Last Earnings Report?

NOV Declares Regular Quarterly Dividend and Supplemental Dividend

Solaris Energy Q1 Earnings Crush Estimates on Power Growth

NOV Q1 Earnings Miss Estimates, Revenues Beat, Decrease Y/Y

While Asia and Europe scramble for natural gas, the US glut has nowhere to go

NOV Inc. (NOV) Q1 2026 Earnings Call Transcript

Compared to Estimates, Nov Inc. (NOV) Q1 Earnings: A Look at Key Metrics

Nov Inc. (NOV) Lags Q1 Earnings Estimates

NOV Reports First Quarter 2026 Earnings

NOV Reports First Quarter 2026 Earnings

Supply Chain de NOV

Upstream

Downstream

Proxies